These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 26201504)

  • 1. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia.
    Estepp JH; Melloni C; Thornburg CD; Wiczling P; Rogers Z; Rothman JA; Green NS; Liem R; Brandow AM; Crary SE; Howard TH; Morris MH; Lewandowski A; Garg U; Jusko WJ; Neville KA;
    J Clin Pharmacol; 2016 Mar; 56(3):298-306. PubMed ID: 26201504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease.
    Wiczling P; Liem RI; Panepinto JA; Garg U; Abdel-Rahman SM; Kearns GL; Neville KA
    J Clin Pharmacol; 2014 Sep; 54(9):1016-22. PubMed ID: 24729271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
    McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA
    Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.
    Estepp JH; Wiczling P; Moen J; Kang G; Mack JM; Liem R; Panepinto JA; Garg U; Kearns G; Neville KA
    Br J Clin Pharmacol; 2018 Jul; 84(7):1478-1485. PubMed ID: 28884840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease.
    de Montalembert M; Bachir D; Hulin A; Gimeno L; Mogenet A; Bresson JL; Macquin-Mavier I; Roudot-Thoraval F; Astier A; Galactéros F
    Haematologica; 2006 Dec; 91(12):1685-8. PubMed ID: 17145606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.
    Dong M; McGann PT; Mizuno T; Ware RE; Vinks AA
    Br J Clin Pharmacol; 2016 Apr; 81(4):742-52. PubMed ID: 26615061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.
    Paule I; Sassi H; Habibi A; Pham KP; Bachir D; Galactéros F; Girard P; Hulin A; Tod M
    Orphanet J Rare Dis; 2011 May; 6():30. PubMed ID: 21619673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do difficulties in swallowing medication impede the use of hydroxyurea in children?
    Bekele E; Thornburg CD; Brandow AM; Sharma M; Smaldone AM; Jin Z; Green NS
    Pediatr Blood Cancer; 2014 Sep; 61(9):1536-9. PubMed ID: 24753149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia.
    Power-Hays A; Dong M; Punt N; Mizuno T; Smart LR; Vinks AA; Ware RE
    Clin Pharmacol Ther; 2024 Sep; 116(3):670-677. PubMed ID: 38018175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of hydroxyurea and bone marrow transplant on Anti-Müllerian hormone (AMH) levels in females with sickle cell anemia.
    Elchuri SV; Williamson RS; Clark Brown R; Haight AE; Spencer JB; Buchanan I; Hassen-Schilling L; Brown MR; Mertens AC; Meacham LR
    Blood Cells Mol Dis; 2015 Jun; 55(1):56-61. PubMed ID: 25976468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
    Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease.
    Bachir D; Hulin A; Huet E; Habibi A; Nzouakou R; El Mahrab M; Astier A; Galacteros F
    Hemoglobin; 2007; 31(4):417-25. PubMed ID: 17994375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia.
    Meier ER; Creary SE; Heeney MM; Dong M; Appiah-Kubi AO; Nelson SC; Niss O; Piccone C; Quarmyne MO; Quinn CT; Saving KL; Scott JP; Talati R; Latham TS; Pfeiffer A; Shook LM; Vinks AA; Lane A; McGann PT
    Trials; 2020 Nov; 21(1):983. PubMed ID: 33246482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
    Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
    Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
    Dong M; Mizuno T; Vinks AA
    Blood Cells Mol Dis; 2017 Sep; 67():143-147. PubMed ID: 28807656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
    Karkoska K; Todd K; Niss O; Clapp K; Fenchel L; Kalfa TA; Malik P; Quinn CT; Ware RE; McGann PT
    Pediatr Blood Cancer; 2021 Jun; 68(6):e29008. PubMed ID: 33742510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of renal function on hydroxyurea exposure in sickle-cell disease patients.
    Pressiat C; Rakotoson MG; Habibi A; Barau C; Arrouasse R; Galactéros F; Stehlé T; Audard V; Hulin A; Bartolucci P
    Br J Clin Pharmacol; 2021 May; 87(5):2274-2285. PubMed ID: 33217005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia.
    Karkoska K; Quinn CT; Niss O; Pfeiffer A; Dong M; Vinks AA; McGann PT
    Am J Hematol; 2021 May; 96(5):538-544. PubMed ID: 33534136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
    Salvia AC; Figueiredo MS; Braga JA; Pereira DF; Brighenti FL; Koga-Ito CY
    J Oral Pathol Med; 2013 Aug; 42(7):570-5. PubMed ID: 23278631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea.
    Lanzkron S; Haywood C; Segal JB; Dover GJ
    Am J Hematol; 2006 Dec; 81(12):927-32. PubMed ID: 16924648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.